Tumor-sequencing blood testing is a rapidly emerging substitute for conventional tumor autopsies, which is developed to acquire the most amount of molecular information about the cancer with least amount of surgical invasion.
The tumor-sequencing blood testing market is expected to grow substantially during the forecast period due to growing incidence of cancer worldwide. The tumor-sequencing blood testing market is segmented on the basis of circulating biomarker, cancer type and end-user.
On the basis of circulating biomarker, the market is segmented into circulating tumor cells, extracellular vesicles, circular tumor DNA and others. With the COVID-19 breakout in December 2019, the disease has affected more than 200 countries. Therefore, it is important to take this into consideration while addressing Tumor-sequencing blood testing Market.
The disease may have led to temporary lag in the Tumor-sequencing blood testing Market, but in the long run the tumor-sequencing blood testing market is expected to pace up and flourish at a significant rate during the forecast period 2020-2030.
The rising incidence of cancer around the globe is expected to drive the growth of the tumor-sequencing blood testing market during the forecast period. Several initiatives undertaken by the government and other organization to spread the awareness is expected to boost the growth of the tumor-sequencing blood testing market.
Growing no. of diagnostic laboratories in developing countries is another factor that may drive the growth of the market. Moreover, technological advancements in developed counties may also contribute towards the growth of the tumor-based blood testing market.
The rise is awareness among the patients regarding the methods that are minimally invasive may also boost the market growth. The benefits offered by tumor sequencing blood testing over solid tissue biopsy may also lead to significant growth in the tumor-sequencing blood testing market.
However, the available alternatives for tumor sequencing blood testing and reimbursements that are unclear and regulation scenario may hinder the growth of the tumor-sequencing blood testing market.
On the basis of circulating biomarker, the Tumor-sequencing blood testing Market is segmented into extracellular vesicles, circulating tumor cells, circular tumor DNA and other biomarker. In this segment, Circulating tumor cells biomarker is expected to contribute highest growth in the tumor-sequencing blood testing market due to its increased investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer.
On the basis of cancer type, the market is segmented into colorectal cancer, liver cancer, prostate cancer, breast cancer, lung cancer and other cancers. Liver and lung cancer is expected to hold the highest revenue in this segment due to the growing prevalence of liver and lung cancer. However, breast cancer is expected to grow in this segment as a result of rising breast cancer cases.
On the basis of end user, the Tumor-sequencing blood testing Market is segmented into hospitals, laboratories, academic & research institutes and others. The hospital and laboratories segment is expected to contribute highest revenue during the forecast period. However, the academic and research institutes are expected to experience exponential growth due to its focus on novel techniques to detect specific disease in real time.
Additionally, the growing investment in research and development by the government in developing countries will further lead to the growth in this segment.
North America is expected to dominate the global Tumor-sequencing blood testing market due to high disease burden of cancer in this region. Moreover, the rising pervasiveness of cancer and the demand for early diagnosis and treatment will further boost the growth of tumor-sequencing blood testing market. Additionally, the presence of accurate and sensitive cancer screening and diagnostics available in this region may also drive the growth of the market.
Europe is considered to experience significant growth prospects in the forecasting years due to growing investment in healthcare infrastructure. However, East Asia is expected to experience significant growth due to availability of funds for research and development.
South Asia is expected to experience highest market growth during the forecast periods due to high consumption of sugar-rich food, increasing adoption of sedentary lifestyle, lesser child-bearing and hormone replacement therapies are few risk factors of developing cancer and which may boost the growth of tumor-sequencing blood testing market.
Furthermore, growing no. of diagnostic laboratories and cancer research institutes are also expected to drive the growth of tumor-sequencing blood testing market in this region. In the Middle East and Africa are expected to experience limited growth due to slow economic growth and under developed healthcare sector.
Some of the players identified in the warm autoimmune hemolytic anemia market include:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global tumor-sequencing blood testing Market has been segmented on the basis of circulating biomarker, cancer type and end user.
Based on Circulating Biomarker:
Based on Cancer Type:
Based on End User:
Explore Similar Insights
Tumor-sequencing Blood Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
